All the Active Ingredient Drugs
Interlukin-1 Inhibitor. Canakinumab 150 mg. VIAL (sol. for inject.): 1. Adults,
adolesc., child over 4 yrs: Bdy wt. > 40
kg: 150 mg; bdy wt. 15 kg-40 kg: 2 mg/
kg. Admin. every 8 wks S.C. inject. as
single dose. If satisfact. clin. response
not achieved 7 days aft. tmt. start,
second dose can be considered.
If full tmt. response achieved, maintain
the intensified dos. regimen of 300 mg and 4 mg/kg every 8 wks. No exper. For
doses >600 mg every 8 wks.
Clin. experience with dos. at intervals
of less than 4 wks limited. See lit.
Tmt. of the follow. autoinflammat.
period. fever syndr. in adults, adolesc.,
child. aged 2 yrs. and older:
Tmt. of CAPS- in adult. adolesc., child.
aged 2 yrs. and older with bdy. wt. of 7.5
kg or above, includ.: MWS, NOMID,
CINCA, sev. form. of FCAS / FCU present.
with signs & sympt. beyond cold-induc.
urticar. skin rash.
Tmt. of TNF recept. assoc. period. syndr.
Hyperimmunoglobulin D syndr.
mevalonate kinase defic.
FMF in pts. in whom colchicine is
contraindic., is not tolerated, or does not
provide an adeq. respon. despite the
highest tolerab. dose of colchicine.
Canakinumab can be given as monother.
or in combin. with colchicine.
SJIA- in pts. aged 4 yrs. and older.
frequent Gouty arthritis in adult pts. with
gouty arthrit. attacks (at least 3 attacks
in the prev. 12 mnths.) in whom NSAIDs &
colchicine are contraindic. ,are not
tolerat., or do not provide an adeq.
response, and in whom repeated courses
of corticoster. are not approp. See lit.
C/I: Hypersens., active, severe infect.